Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium
| Autor: | Bastian Neesgaard, Amanda Mocroft, Robert Zangerle, Ferdinand Wit, Fiona Lampe, Huldrych F Günthard, Coca Necsoi, Matthew Law, Cristina Mussini, Antonella Castagna, Antonella d'Arminio Monforte, Christian Pradier, Nikoloz Chkhartisvilli, Juliana Reyes-Uruena, Jörg Janne Vehreschild, Jan-Christian Wasmuth, Anders Sönnerborg, Christoph Stephan, Lauren Greenberg, Josep M Llibre, Alain Volny-Anne, Lars Peters, Annegret Pelchen-Matthews, Vani Vannappagari, Joel Gallant, Armin Rieger, Mike Youle, Dominique Braun, Stephane De Wit, Kathy Petoumenos, Vanni Borghi, Vincenzo Spagnuolo, Tengiz Tsertsvadze, Jens Lundgren, Lene Ryom, RESPOND study group |
|---|---|
| Přispěvatelé: | Neesgaard, B., Mocroft, A., Zangerle, R., Wit, F., Lampe, F., Gunthard, H. F., Necsoi, C., Law, M., Mussini, C., Castagna, A., Monforte, A. D., Pradier, C., Chkhartisvilli, N., Reyes-Uruena, J., Vehreschild, J. J., Wasmuth, J. -C., Sonnerborg, A., Stephan, C., Greenberg, L., Llibre, J. M., Volny-Anne, A., Peters, L., Pelchen-Matthews, A., Vannappagari, V., Gallant, J., Rieger, A., Youle, M., Braun, D., de Wit, S., Petoumenos, K., Borghi, V., Spagnuolo, V., Tsertsvadze, T., Lundgren, J., Infectious diseases, APH - Aging & Later Life |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Male Psychologie appliquée Integrase inhibitor Blood Pressure HIV Infections Cardiovascular Medicine Vascular Medicine HIV Integrase Inhibitors/therapeutic use Geographical Locations Cohort Studies Endocrinology Medical Conditions 0302 clinical medicine Chronic Kidney Disease Medicine and Health Sciences Medicine Public and Occupational Health 030212 general & internal medicine Immune Response education.field_of_study Multidisciplinary Reverse-transcriptase inhibitor Pharmaceutics Sciences bio-médicales et agricoles Middle Aged Viral Load Vaccination and Immunization Europe Cardiovascular Therapy Treatment Outcome Nephrology Cardiovascular Diseases Hypertension Cohort Reverse Transcriptase Inhibitors Female Biologie Viral load Research Article medicine.drug Adult medicine.medical_specialty Reverse Transcriptase Inhibitors/therapeutic use Endocrine Disorders Science Immunology Population Cardiology HIV Infections/drug therapy Antiretroviral Therapy HIV/drug effects HIV Protease Inhibitors/therapeutic use 03 medical and health sciences Antiviral Therapy Drug Therapy Internal medicine Diabetes Mellitus Renal Diseases Humans HIV Integrase Inhibitors education business.industry Biology and Life Sciences HIV Odds ratio HIV Protease Inhibitors 030112 virology Confidence interval Viral Load/drug effects CD4 Lymphocyte Count Regimen Metabolic Disorders People and Places Preventive Medicine business |
| Zdroj: | Neesgaard, B, Mocroft, A, Zangerle, R, Wit, F, Lampe, F, Günthard, H F, Necsoi, C, Law, M, Mussini, C, Castagna, A, Monforte, A DA, Pradier, C, Chkhartisvilli, N, Reyes-Uruena, J, Vehreschild, J J, Wasmuth, J-C, Sönnerborg, A, Stephan, C, Greenberg, L, Llibre, J M, Volny-Anne, A, Peters, L, Pelchen-Matthews, A, Vannappagari, V, Gallant, J, Rieger, A, Youle, M, Braun, D, De Wit, S, Petoumenos, K, Borghi, V, Spagnuolo, V, Tsertsvadze, T, Lundgren, J, Ryom, L & RESPOND Study Group 2020, ' Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting : The RESPOND cohort consortium ', PLoS ONE, vol. 15, no. 12, e0243625 . https://doi.org/10.1371/journal.pone.0243625 PLoS ONE r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname PLoS ONE, Vol 15, Iss 12, p e0243625 (2020) PLoS ONE, 15(12 December):e0243625. Public Library of Science PloS one, 15 (12 December |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0243625 |
| Popis: | Objectives To compare virologic and immunologic outcomes of integrase inhibitor (INSTI)-containing, contemporary boosted protease inhibitor (PI/b)-containing and non-nucleotide reverse transcriptase inhibitor (NNRTI)-containing regimens in a real-life setting. Methods Using logistic regression, virologic and immunologic outcomes of INSTI use were compared to outcomes of PI/b or NNRTI treatment 12 months after treatment start or switch, for participants in the RESPOND cohort consortium. A composite treatment outcome (cTO) was used, defining success as viral load (VL) SCOPUS: ar.j info:eu-repo/semantics/published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|